Discussion about this post

User's avatar
Jasper's avatar

"the implied value of SRNE’s SCLX’s shares are worth much more than SCLX’s stock price" -- I think you mean SRNE's stock price here.

Expand full comment
MikeFromNZ's avatar

I'm long SCLX, which I think is the best vehicle for exploiting this situation.

You omit discussing the fundamentals of SRNE and SCLX, no doubt for brevity, but as you are no doubt aware, SCLX has been executing well in terms of getting coverage for and selling ZTlido® and in progressing their pipeline, including SP-102, which is in P3 trials for sciatica pain.

I think SCLX is the preferred vehicle since:

1. It's the subject of the orchestrated short squeeze (duh ... most professional investors are too smart for their own good, so KISS and embrace your squeeze)

2. If you're playing the squeeze rather than fundamentals, by definition you don't care about SOTP, so forget about SRNE

3. While SCLXW theoretically offers more leverage, you likewise shouldn't expect SCLXW to reflect the squeezed value of SCLX (as evidenced by today's price action, where at the time of ranting, SCLX is up more than SCLXW)

4. SCLX is also more liquid than SCLXW, and since it trades 4.5x higher, you can put more capital to work.

I'm looking forward to the sequel where you discus the endgame for SRNE.

Expand full comment
23 more comments...